Related Experiment Videos
[Prolonged curarization with suxamethonium in a four-week old infant]
D Michel1, L Simon, M M Garbay
1Département d'anesthésie-réanimation, hôpital Saint-Vincent-de-Paul, Paris, France.
Annales Francaises D'Anesthesie Et De Reanimation
|September 29, 1998
Insights
A 28-day-old infant experienced prolonged apnea after anesthesia due to a genetic condition, atypical cholinesterase. This case highlights the importance of identifying genetic factors for adverse drug reactions in infants undergoing surgery.
Area of Science:
- Anesthesiology
- Clinical Pharmacology
- Human Genetics
Background:
- Infants undergoing anesthesia for conditions like pyloric stenosis are at risk for prolonged apnea.
- Suxamethonium is a muscle relaxant commonly used in pediatric anesthesia.
- Atypical cholinesterase is a genetic variant affecting drug metabolism.
Observation:
- A 28-day-old infant developed prolonged apnea post-anesthesia.
- The infant was administered suxamethonium during surgery for pyloric stenosis.
- Genetic testing revealed the infant was homozygous for atypical cholinesterase.
Findings:
- Homozygosity for atypical cholinesterase is a rare genetic disorder.
- This genetic variant significantly prolongs the action of suxamethonium.
- The infant's prolonged apnea was directly linked to suxamethonium metabolism deficiency.
Implications:
- Early identification of atypical cholinesterase is crucial for safe anesthesia practices.
- Genetic screening may be considered for infants with a family history of adverse reactions to suxamethonium.
- Understanding genetic variations improves patient safety and anesthetic management in pediatric surgery.
Abstract:
A case of a 28-day-old infant who developed suxamethonium apnoea is described. He was found to be homozygous for atypical cholinesterase. Main characteristics of this disorder are reviewed. Other causes of prolonged apnoea in infants recovering from anaesthesia for surgery of pyloric stenosis are discussed.